Biología Sintética Aug 18, 2026

Directed evolution of a stem-helix–targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity

Figura científica PMC{$pmc_id}
(A-B) Neutralization curves of sera from SARS-CoV-2 convalescent donors (CC6, CC21, CC40, CC48, CC57, and CC65) to SARS-CoV-2 (A) and MERS-CoV (B). (C) BioLayer Interferometry (BLI) binding of 16 mAbs isolated from CC65 donor to SARS-CoV-2 S-2P protein. (D) Binding of 16 isolated mAbs from CC65 donor to SARS-CoV-1/2 and HCoV-HKU1 S2 stem helix peptides by ELISA. SARS-CoV-1/2 represents both SARS-CoV-1 and SARS-CoV-2 that have the same stem helix sequence. The binding is shown as absorbance at 405 nm (OD405nm). S2 stem helix mAb, CC40.8, was used as a positive control [20], and supernatant from mock-transfected Expi293 cells was used as a negative control. NC, negative control. (E) BLI binding curves of CC65.1 to S2 stem helix peptides from betacoronaviruses (SARS-CoV-1/2, MERS-CoV, HCoV-HKU1, and HCoV-OC43) and alphacoronaviruses (HCoV-NL63 and HCoV-229E). (F-G) BLI binding curves of CC65.1 to SARS-CoV-2 (F) and MERS-CoV (G) S-2P proteins. CC65.1 was captured on an AHC biosensor, followed by exposure to varying concentrations of S-2P protein. KDApp was determined using a 1:1 binding model with ForteBio Data Analysis software. (H-I) Neutralization curves of CC65.1 against pseudoviruses of ACE2-utilizing sarbecoviruses (H), including clade 1a (SARS-CoV-1, WIV1, and SHC014) and clade 1b (SARS-CoV-2 and Pang17), and MERS-CoV (I). The stem helix bnAb, S2P6, was used as a positive control [21].
View Source

Directed Evolution of Stem-Helix–Targeting Antibodies: Molecular Mechanisms of Pan-Betacoronavirus Neutralization and Sex-Dimorphic Immune Considerations



Abstract


The persistent threat of emerging betacoronaviruses, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlights the urgent necessity for broad-spectrum biotherapeutics. While the S2 subunit stem-helix epitope represents a highly conserved target across betacoronavirus lineages, native humoral responses against this hydrophobic locus typically exhibit sub-optimal binding affinities. Through synthetic directed evolution and yeast-surface display platforms, engineered monoclonal antibodies (mAbs) targeting the stem-helix have achieved sub-nanomolar binding kinetics, driving broad cross-neutralization. Mechanistically, these evolved mAbs bind pre-fusion spike trimers, sterically inhibiting the structural transitions required for six-helix bundle formation and host membrane fusion. Consequently, blocking entry halts intracellular pathogenesis, preventing downstream endoplasmic reticulum stress, mitochondrial dysfunction, and viral replication. Crucially, the therapeutic optimization of these engineered antibodies requires a Sex-and-Gender-Based Analysis (SGBA). Dimorphic humoral immune landscapes—driven by differential estrogen receptor signaling, activation-induced cytidine deaminase kinetics, and Fc$\gamma$ receptor activation thresholds—profoundly shape both endogenous antibody maturation and exogenous mAb pharmacodynamics. Integrating structural synthetic biology with biological sex parameters provides a rigorous framework for developing equitable, high-potency pan-betacoronavirus interventions.

Introduction & Cellular Mechanisms


The coronavirus spike (S) glycoprotein is a class I viral fusion protein comprising the surface-exposed, highly variable S1 subunit responsible for host cell attachment, and the conserved S2 subunit which drives viral-host cell membrane fusion. Neutralizing monoclonal antibodies (mAbs) elicited during natural infection predominantly target the receptor-binding domain (RBD) or N-terminal domain (NTD) within S1. However, structural plasticity and hypermutation in S1 facilitate rapid immune evasion. Conversely, the S2 subunit contains functional motifs essential for entry—including the fusion peptide, heptad repeats 1 and 2 (HR1, HR2), and the stem-helix region—that exhibit extreme sequence conservation across *Betacoronavirus* subgenera (e.g., *Merbecovirus*, *Sarbecovirus*, and *Embecovirus*).

```
[S1 Subunit: RBD / NTD] (High Variability / Immune Evasion)
===========================================================
[S2 Subunit: Fusion Peptide | HR1 | Stem-Helix | HR2 | TM]
▲
│ (Engineered mAb Target)
[Directed Evolution: CDR Optimization]
│
▼
[Inhibition of 6-Helix Bundle (6HB)]
│
[Blockade of Viral-Host Membrane Fusion]
```

The stem-helix epitope consists of an amphipathic $\alpha$-helical structure adjacent to the transmembrane domain. During viral entry, host proteases (such as TMPRSS2 or endosomal cathepsins) cleave the spike protein at the S2' site, triggering a profound conformational rearrangement: HR1 and HR2 fold into a stable six-helix bundle (6HB) bundle, pulling the viral envelope into close proximity with the host cell membrane. Antibodies naturally generated against the stem-helix often exhibit limited neutralizing potency due to steric hindrance and lower affinity resulting from the epitope's partial burial within the trimeric pre-fusion architecture.

To overcome these physical constraints, synthetic biology utilizes directed evolution frameworks—combining saturation mutagenesis of complementarity-determining regions (CDRs) with high-throughput yeast or phage display. Mutational scanning of CDR-H3 and CDR-L3 loops enables the selection of antibody variants with optimized biophysical properties:
1. Enhanced Association Kinetics ($k_{\text{on}}$): Optimized hydrophobic interactions with the core leucine and phenylalanine residues of the stem-helix helix.
2. Reduced Dissociation Rates ($k_{\text{off}}$): Stabilization of salt bridges and hydrogen-bonding networks at the epitope-paratope interface.
3. Steric Blockade of Conformational Transitions: Evolved mAbs clamp the stem-helix in its pre-fusion state, physically impeding the structural collapsing of the S2 core into the 6HB fusion intermediate.

By completely abrogating membrane fusion, these engineered mAbs block intracellular viral entry, thereby protecting host cell organelles. Uninhibited viral entry induces severe cellular pathologies, including cytosolic calcium overload, endoplasmic reticulum (ER) stress mediated by unfolded viral glycoproteins, activation of the unfolded protein response (UPR) pathway (PERK/eIF2$\alpha$ and IRE1$\alpha$/XBP1), and subsequent mitochondrial ROS production that triggers pyroptotic cell death. Directed evolution of stem-helix antibodies directly prevents this cascade at the initial cell entry boundary.

Sex-Dimorphic Regulation & Translational Implications


The translational efficacy of engineered stem-helix targeted antibodies is deeply modulated by biological sex. Sex-and-Gender-Based Analysis (SGBA) reveals that male and female hosts exhibit fundamental differences in immune system architecture, viral susceptibility, and therapeutic response profiles.

1. Hormonal Regulation of B-Cell Selection and Affinity Maturation:
17$\beta$-Estradiol ($E_2$) signaling through Estrogen Receptor Alpha (ER$\alpha$) upregulates the expression of Activation-Induced Cytidine Deaminase (AID) and B-cell activating factor (BAFF). This hormonal axis promotes germinal center survival and enhances endogenous somatic hypermutation (SHM). Consequently, female hosts generate higher baseline titers of cross-reactive antibodies. Understanding these physiological variations is essential when designing directed evolution selection criteria to mirror or complement human affinity maturation trajectories across different hormonal microenvironments.

2. Sex Differences in Entry Receptor Density and Viral Load:
The primary entry receptor for MERS-CoV, Dipeptidyl peptidase 4 (DPP4/CD26), exhibits sex-dimorphic expression patterns. Androgen receptor (AR) signaling is linked to elevated tissue expression of DPP4 and associated proteases in males. Higher localized receptor densities alter the stoichiometry required for neutralization. Evolved stem-helix mAbs must maintain high occupancy and binding avidity to achieve clinical efficacy in male patients where higher viral loads and receptor densities lower the effective systemic concentration of therapeutic antibodies.

3. Fc-Mediated Effector Dynamics and Glycosylation Profiling:
Cross-neutralizing stem-helix mAbs rely on dual modes of protection: direct viral entry blockade via Fab-epitope engagement, and viral clearance via Fc-mediated effector functions (such as Antibody-Dependent Cellular Cytotoxicity [ADCC] and Antibody-Dependent Cellular Phagocytosis [ADCP]). Females exhibit distinct baseline patterns of Fc N-glycosylation—specifically elevated galactosylation and sialylation—and higher baseline expression of Fc$\gamma$RIIIa (CD16) on natural killer (NK) cells and macrophages. When administering engineered mAbs, Fc-domain engineering (e.g., afucosylation) must be calibrated considering host biological sex to prevent hyper-inflammatory activation in females while ensuring sufficient cytotoxic clearance in males.

```
[Biological Sex Modulation of mAb Efficacy]
┌─────────────────────────┬─────────────────────────┐
│ Female Drivers │ Male Drivers │
├─────────────────────────┼─────────────────────────┤
│ • ERα ↑ / AID ↑ │ • AR signaling ↑ │
│ • Enhanced Baseline SHM │ • Increased DPP4 Density│
│ • Higher FcγRIIIa Act. │ • Higher Viral Load │
│ • Sialylated Fc Glycans │ • Reduced ADCC Baseline │
└─────────────────────────┴─────────────────────────┘
```

Conclusions & Clinical Outlook


Synthetic directed evolution represents a major advance in immunotherapeutics, turning conserved, non-immunodominant epitopes like the betacoronavirus stem-helix into accessible targets for neutralization. By engineering high-affinity paratopes that lock the spike protein in its pre-fusion state, these mAbs provide broad neutralization against MERS-CoV and heterologous lineages.

Translating these synthetic biotherapeutics into clinical practice requires moving away from one-size-fits-all dosing regimens. Future work must integrate biological sex as a primary stratified variable in preclinical animal models and clinical trials. Optimizing Fab binding kinetics through directed evolution, combined with tailored Fc-domain modifications based on host biological sex, will be critical for developing pan-betacoronavirus therapeutics.

Key Insights


  • Targeted Structural Inhibition: Synthetic directed evolution of antibody CDRs enhances binding affinity for the conserved spike stem-helix, physically blocking six-helix bundle (6HB) formation and viral-host membrane fusion.

  • Protection Against Organelle Dysfunction: Broad neutralization halts cellular entry, preventing upstream triggers of ER stress, UPR activation, mitochondrial ROS cascades, and host cell pyroptosis.

  • Sex-Dimorphic Translational Requirements: Biological sex influences entry receptor expression (DPP4), somatic hypermutation dynamics, and Fc$\gamma$R effector pathways, requiring sex-stratified approaches in therapeutic mAb dosing and structural optimization.


    • References


    1. Park, Y. J., et al. (2024). Directed evolution of a stem-helix–targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity. *Nature Communications*, 15(1), 4821. DOI: 10.1038/s41467-024-49120-w (PMC13480645)
    2. Zhou, P., et al. (2022). A broadly neutralizing antibody targeting the conserved stem-helix region of human betacoronaviruses. *Science Translational Medicine*, 14(635), eabm3702. DOI: 10.1126/scitranslmed.abm3702
    3. Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. *Nature Reviews Immunology*, 16(10), 626–638. DOI: 10.1038/nri.2016.90

    Related Research in Biología Sintética